A Phase 2 interventional study of Zanubrutinib in Relapsed Diffuse Large B-cell Lymphoma and Refractory Diffuse Large B-cell Lymphoma, sponsored by BeiGene. Completed at 25 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse — 19 open to participants now, 23 under way, 1 of them phase 3. zanubrutinib · Lymphoma, Large B-Cell, Diffuse.
Among the 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 7th largest by enrollment, is one of 4 that started in 2021, is one of 26 in phase 2, and was the 8th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →19 of the 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 2 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18+
Beijing Tongren Hospital · Sites in China
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Shanghai Zhongshan Hospital · Sites in China
Ages 70+
Virginia Commonwealth University · Sites in United States
Ages 18+
By country, each count listing its studies:
zanubrutinib: first FDA approval 2019 (BRUKINSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 39 across the 30 interventional studies. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
10 studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines: 3 open now, 3 under way, none of them phase 3. Of 7 finished, 6 (86%) have results posted.
Among the 10 studies in Lymphoma, Large B-Cell, Diffuse by BeOne Medicines, this one is the 6th largest by enrollment, is one of 2 that started in 2021, is one of 3 in phase 2, and was the 6th registered.
BeOne Medicines’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 2017.
3 of the studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06669143Ruijin HospitalZanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission | 2026-11 |
| NCT05873712Aseel AlsouqiZanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | 2026-12-31 |
| NCT07012980Shanghai Zhongshan HospitalGlofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies testing zanubrutinib in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among BeOne Medicines’s 10 in Lymphoma, Large B-Cell, Diffuse:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial was to evaluate whether zanubrutinib can effectively treat adults with CD79B-mutant relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Participants received zanubrutinib as monotherapy, underwent regular disease assessments to evaluate treatment response, and were monitored for safety and side effects throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants had disease prior to study entry, defined as either:
Participants were ineligible for high-dose therapy and stem cell transplantation, defined as meeting at least one of the following criteria:
a. Presence of significant organ dysfunction, such as:
b. Failure to achieve a complete response or partial response following salvage therapy.
c. Failure to collect stem cells or inability to undergo stem cell collection, as assessed by the investigator.
Exclusion Criteria
Participants had non-Hodgkin lymphoma other than classical histology diffuse large B-cell lymphoma (not otherwise specified), including but not limited to:
Participants had received any of the following treatments within the specified timeframe prior to the first dose of study drug:
Participants had a history of other active within two years prior to study entry, with the exception of:
Note: Other protocol-defined inclusion and exclusion criteria may have applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received zanubrutinib 160 mg orally twice daily, administered continuously until disease progression, unacceptable toxicity, withdrawal of consent, initiation of alternative anticancer therapy, loss to follow-up, or study completion.
Drug: Zanubrutinib
Administered orally as capsules at a dose of 160 mg twice daily on a continuous dosing schedule.
Also known as: BGB-3111, Brukinsa
Overall Response Rate (ORR)
Defined as the percentage of participants who achieved complete response (CR) or partial response (PR) by investigator assessment according to the Lugano classification for Non-Hodgkin's Lymphoma (NHL).
Time frame: Response was assessed every 12 weeks for the first 24 months and every 24 weeks thereafter. Maximum time on study was 36.4 months
Complete Response Rate (CRR)
CRR was defined as the percentage of participants who achieved a complete response as their best overall response, as determined by investigator assessment according to the Lugano classification for NHL.
Time frame: Response was assessed every 12 weeks for the first 24 months and every 24 weeks thereafter. Maximum time on study was 36.4 months
Duration of Response (DOR)
DOR was defined as the time from the date that a confirmed response (CR or PR) was first observed to the date of first documented disease progression or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method.
Time frame: From the date of first documented response until to the data cutoff date (31MAR2025). Maximum time on study was 36.4 months
Progression-free Survival (PFS)
PFS is defined as time from start of treatment to the first documentation of disease progression or death, whichever occurs first as determined by investigator assessment according to the Lugano classification for NHL. Median PFS was estimated using the Kaplan-Meier method.
Time frame: From first dose until the data cutoff date (31MAR2025). Maximum time on study was 36.4 months
Time to Response (TTR)
TRR was defined as the time from randomization to the first date that response criteria (CR or PR) were met, as determined by investigator assessment per the Lugano classification for NHL. Only participants who achieved an overall response were included in the analysis.
Time frame: From first dose until disease progression or death, assessed up to the data cutoff date (31MAR2025). Maximum time on study was 36.4 months
Overall Survival (OS)
OS was defined as the time from randomization to the date of death from any cause. Median OS was estimated using the Kaplan-Meier method.
Time frame: From first dose until the data cutoff date (31MAR2025). Maximum time on study was 36.4 months
Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An adverse event refers to any unintended or unfavorable sign, symptom, or condition (including abnormal lab results) that occurs during the study, regardless of whether it was linked to the study drug.
Time frame: From the first dose until 30 days after the last dose of zanubrutinib, death, or initiation of new anticancer therapy, whichever occurred first, assessed up to the data cutoff date (31MAR2025). Maximum treatment duration was 36.4 months
Participants were enrolled at 20 study centers in China.
| Milestone | Zanubrutinib |
|---|---|
| Started | 65 |
| Treated | 65 |
| Completed | 16 |
| Not completed | 49 |
| Withdrew: Death | 32 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Study completed by sponsor | 14 |
Defined as the percentage of participants who achieved complete response (CR) or partial response (PR) by investigator assessment according to the Lugano classification for Non-Hodgkin's Lymphoma (NHL).
| percentage of participants | Zanubrutinib |
|---|---|
| Overall Response Rate (ORR) | 46.2 (33.7 to 59.0) |
CRR was defined as the percentage of participants who achieved a complete response as their best overall response, as determined by investigator assessment according to the Lugano classification for NHL.
| Percentage of Participants | Zanubrutinib |
|---|---|
| Complete Response Rate (CRR) | 29.2 (18.6 to 41.8) |
DOR was defined as the time from the date that a confirmed response (CR or PR) was first observed to the date of first documented disease progression or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method.
| Months | Zanubrutinib |
|---|---|
| Duration of Response (DOR) | 22.7 (2.8 to NA) |
PFS is defined as time from start of treatment to the first documentation of disease progression or death, whichever occurs first as determined by investigator assessment according to the Lugano classification for NHL. Median PFS was estimated using the Kaplan-Meier method.
| Months | Zanubrutinib |
|---|---|
| Progression-free Survival (PFS) | 4.3 (2.7 to 5.5) |
TRR was defined as the time from randomization to the first date that response criteria (CR or PR) were met, as determined by investigator assessment per the Lugano classification for NHL. Only participants who achieved an overall response were included in the analysis.
| Months | Zanubrutinib |
|---|---|
| Time to Response (TTR) | 2.76 (0.9 to 5.5) |
OS was defined as the time from randomization to the date of death from any cause. Median OS was estimated using the Kaplan-Meier method.
| Months | Zanubrutinib |
|---|---|
| Overall Survival (OS) | 18.1 (11.4 to NA) |
An adverse event refers to any unintended or unfavorable sign, symptom, or condition (including abnormal lab results) that occurs during the study, regardless of whether it was linked to the study drug.
| Participants | Zanubrutinib |
|---|---|
| At Least One TEAE | 59 |
| At Least One SAE | 16 |
Collected over From the first dose until 30 days after the last dose of zanubrutinib or initiation of new anticancer therapy, whichever occurred first, assessed up to the data cutoff date (31MAR2025). Maximum treatment duration was 36.4 months. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zanubrutinib | 32/65 (49.2%) | 16/65 (24.6%) | 57/65 (87.7%) |
| Event | Zanubrutinib |
|---|---|
| PneumoniaInfections and infestations | 4/65 |
| Acute coronary syndromeCardiac disorders | 1/65 |
| Abdominal adhesionsGastrointestinal disorders | 1/65 |
| AscitesGastrointestinal disorders | 1/65 |
| Gastrointestinal perforationGastrointestinal disorders | 1/65 |
| Ileal perforationGastrointestinal disorders | 1/65 |
| IleusGastrointestinal disorders | 1/65 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/65 |
| Chest discomfortGeneral disorders | 1/65 |
| Sudden cardiac deathGeneral disorders | 1/65 |
| Event | Zanubrutinib |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 22/65 |
| Neutrophil count decreasedInvestigations | 22/65 |
| Platelet count decreasedInvestigations | 20/65 |
| White blood cell count decreasedInvestigations | 19/65 |
| Aspartate aminotransferase increasedInvestigations | 13/65 |
| Blood lactate dehydrogenase increasedInvestigations | 12/65 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 12/65 |
| PyrexiaGeneral disorders | 11/65 |
| Alanine aminotransferase increasedInvestigations | 11/65 |
| PneumoniaInfections and infestations | 9/65 |
The Safety Analysis Set included all participants who received at least 1 dose of zanubrutinib.
| Age, Continuous(years) | Zanubrutinib |
|---|---|
| Mean | 65.3 ± 9.88 |
| Sex: Female, Male(Participants) | Zanubrutinib |
|---|---|
| Female | 31 |
| Male | 34 |
| Race/Ethnicity, Customized(Participants) | Zanubrutinib |
|---|---|
| Asian | 65 |
| The Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Zanubrutinib |
|---|---|
| 0 (fully Active) | 12 |
| 1 (Limited strenuous activity; light work possible) | 43 |
| 2 (Self-care intact; no work; up >50% of day) | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beonemedicines.com
Ran from Aug 2021 to primary completion in Mar 2025, 43 months.
Results were first posted in Mar 2026, 11 months after primary completion.
Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 43 months is above that.
Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zanubrutinib
Lymphoma, Large B-Cell, Diffuse →